Retatrutide — Eli Lilly's triple-receptor agonist — delivered 28.3% weight loss in the TRIUMPH-1 Phase 3 trial (May 2026). That rivals bariatric surgery. But you can't get a prescription yet. Here's the realistic timeline.
Where It Stands
TRIUMPH-1 results are in: 2,339 participants, 28.3% average weight loss at the highest dose (12mg) over 80 weeks. 45.3% of patients lost 30% or more. An extension study showed 30.3% loss at 104 weeks. Seven additional TRIUMPH trials are expected to report through 2026, including data at the American Diabetes Association meeting in June.
The Realistic Timeline
| Milestone | Expected |
|---|---|
| Phase 3 TRIUMPH-1 results | ✅ May 2026 (complete) |
| Additional TRIUMPH trials | Throughout 2026 |
| FDA submission | Late 2026 – Early 2027 |
| FDA review period | ~10-12 months after submission |
| Earliest possible approval | Late 2027 – Early 2028 |
| Broad availability | 2028 |
What to Do Now
Waiting for retatrutide means waiting 18-24 months minimum. Today's GLP-1 options — semaglutide (15% weight loss) and tirzepatide (21% weight loss) — are proven, available, and affordable through telehealth. Every month you wait is a month of potential health improvement you're leaving on the table.
Oak Longevity $130/mo flat · Flat-rate pricing at any dose. $130/mo semaglutide, $199/mo tirzepatide. Free coaching. Cancel anytime.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
GobyMeds $99/mo sema, $133/mo tirz · Direct-to-consumer. Semaglutide $99/mo bundle, tirzepatide $133/mo bundle. Code x7X72r saves $25.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.